The new Juno Hazel test has been designed for screening common chromosomal aberrations, including trisomy 21, 18, and 13, in pregnant women using a small amount of blood from a finger prick.
It improves early access to genetic testing without long lead times and eliminates the requirement for phlebotomy.
The test uses the company’s JunoDx Sample Collection Kit which enables immediate blood plasma generation for subsequent laboratory testing from a few blood drops. This increases access, improves NIPS experience, while reducing cost.
Juno Hazel can be performed as early as nine weeks of pregnancy and has no risk of miscarriage.
JunoDx chief medical officer Mathias Ehrich said: “We spent the last few years building a foundation of exceptional science that catalysed the high performance of Juno Hazel.
“Since then, we have demonstrated greater than 99% sensitivity and specificity to detect multiple chromosomal abnormalities.
“Above all, we began this journey to improve prenatal care for all, including traditionally underserved communities.”
The company aims to develop a platform that improves access to prenatal screenings, as well as information for all pregnant women.
By collaborating with physicians and genetic counsellors, it will facilitate a higher level of prenatal care through Juno Hazel and NIPS services, along with curated educational resources and personalised genetic counselling support.
JunoDx CEO and founder Dirk van den Boom said: “We are developing next-generation NIPS solutions that are highly accurate, affordable, and accessible to millions of women and families, delivering a higher standard of care.
“We see tremendous opportunity for our novel approach to blood-based testing, such as NIPS, and are excited to expand our commercial footprint beyond Juno Birch.”
Furthermore, the company intends to expand its portfolio of NIPS with adjacent products and services.